ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI funds nine centers for $14.9 million integrative biology program.

October 29, 2004

ONS Calls For Changes To Resolve Nurse Shortage

June 8, 2001

Researchers Link Cancer Risk And DMPA Birth Control Use

April 27, 2012

CTEP Drafts FDA Approval Guidelines

March 4, 1988

Oncology Unit – How To Plan, Start It

February 10, 1978

Reviewers Note Major Flaws In Design Of Burzynski’s Trials

September 25, 1998